Basic Information
VIS ID
TVIS30013987
Fusion event
HIV-BACH2 integration
Validated
Yes
Detection method
invPCR
Data source
download(RID)
Sample type
PBMC
Disease
HIV-infected disease (HID)
Quality evaluation
Normal
Reported year
2007
PubMed ID
17262715
Virus Sequence
Virus name
HIV
Reference genome
Not given
Host Sequence
Chromosome
chr6
Cytoband
q15
Reference genome
GRCh37/hg19
Start
90751126/90041407 (Hg38)
End
90751126/90041407 (Hg38)
Orient
-
Location type
Intronic
Fragile sites / regions
FRA6G
Target gene
BACH2
miRNAs that regulate target gene
hsa-mir-335-5p ; hsa-mir-29c-3p ; hsa-mir-615-3p ; hsa-mir-8064 ; hsa-mir-1277-5p ; hsa-mir-190a-3p ; hsa-mir-6083 ; hsa-mir-5011-5p ; hsa-mir-656-3p ; hsa-mir-410-3p ; hsa-mir-3942-3p ; hsa-mir-1324 ; hsa-mir-8485 ; hsa-mir-6797-3p ; hsa-mir-6076 ; hsa-mir-6807-3p ; hsa-mir-217 ; hsa-mir-509-5p ; hsa-mir-509-3-5p ; hsa-mir-4418 ; hsa-mir-6749-3p ; hsa-mir-211-5p ; hsa-mir-204-5p ; hsa-mir-2355-5p ; hsa-mir-15b-3p ; hsa-mir-4685-3p ; hsa-mir-4287 ; hsa-mir-6832-3p ; hsa-mir-620 ; hsa-mir-1270 ; hsa-mir-4531 ; hsa-mir-5703 ; hsa-mir-4516 ; hsa-mir-4434 ; hsa-mir-5695 ; hsa-mir-3145-5p ; hsa-let-7g-3p ; hsa-let-7a-2-3p ; hsa-mir-374b-5p ; hsa-mir-374a-5p ; hsa-mir-4791 ; hsa-mir-3201 ; hsa-mir-5692c ; hsa-mir-5692b ; hsa-mir-369-3p ; hsa-mir-5583-3p ; hsa-mir-4517 ; hsa-mir-557 ; hsa-mir-507 ; hsa-mir-4726-3p ; hsa-mir-6764-5p ; hsa-mir-1915-3p ; hsa-mir-6840-3p ; hsa-mir-142-5p
Nearest miRNA
hsa-mir-10398/Upstream/11502098; hsa-mir-1202/Downstream/271335;
Nearest TSS
ENST00000381078/Upstream/32580; ENST00000569865/Downstream/176838;
Nearest CpG islands
None/Target, chr6-CpG: 120/Upstream/153473, chr6-CpG: 227/Downstream/253669
Upstream sequence
ataataattttatGttaaggaggtatccatcacttctgattttataaagtggtttttaatgaaaatagatgttgaattacatcaatgcctttgcagcatc
Downstream sequence
tatgaacatgatcaaataagtgttccttaaagatctattaatatgataaattatattaaaagatttttccaatatttatcactcctggaatgaacctcat
Reference
Ikeda, T., et al. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis,2007, 195(5): 716-725.
Curate